Camp4 Reports Q2 Revenue Beats Estimates
Camp4 Therapeutics (NASDAQ:CAMP), a clinical-stage biotechnology firm specializing in RNA-based genetic disease therapies, delivered its second quarter 2025 results on August 14, 2025. The company reported its first significant recognized revenue at $1.497 million (GAAP), handily beating the consensus GAAP estimate of $0.57 million. The GAAP net loss per share improved to $(0.62) compared to the analyst expectation of $(0.67) (GAAP). These results were supported by progress in clinical development and increased collaboration revenue, though the company remains pre-commercial with a narrowing cash runway. Overall, the period reflected notable operational momentum against a backdrop of persistent investment in research and development.
Source: Analyst estimates for the quarter provided by FactSet.
Camp4 Therapeutics is developing a proprietary technology known as the RNA Actuating Platform (RAP Platform). This technology identifies and targets specific regulatory RNAs (regRNAs) to upregulate the expression of genes implicated in genetic diseases. The ultimate goal is to create a new class of therapies that restore healthy protein levels in patients affected by diseases that lack effective treatments.
Source Fool.com
